Avantor, Inc. (NYSE:AVTR – Get Free Report) has been given an average rating of “Moderate Buy” by the sixteen analysts that are currently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $26.71.
Several brokerages have recently commented on AVTR. Royal Bank of Canada increased their target price on shares of Avantor from $28.00 to $29.00 and gave the company an “outperform” rating in a report on Thursday, February 15th. Barclays lifted their target price on shares of Avantor from $27.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 10th. UBS Group increased their price target on Avantor from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. Deutsche Bank Aktiengesellschaft boosted their price objective on Avantor from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Thursday. Finally, Raymond James lifted their target price on Avantor from $22.50 to $26.00 and gave the stock an “outperform” rating in a research note on Friday, January 26th.
Check Out Our Latest Stock Report on Avantor
Insider Transactions at Avantor
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Veracity Capital LLC increased its stake in shares of Avantor by 48.8% during the first quarter. Veracity Capital LLC now owns 53,214 shares of the company’s stock valued at $1,361,000 after buying an additional 17,458 shares during the period. First Trust Direct Indexing L.P. increased its position in Avantor by 14.5% during the 1st quarter. First Trust Direct Indexing L.P. now owns 11,242 shares of the company’s stock valued at $287,000 after purchasing an additional 1,425 shares during the period. Norden Group LLC bought a new position in Avantor in the 1st quarter worth $1,233,000. Dudley & Shanley Inc. boosted its stake in shares of Avantor by 1.1% during the 1st quarter. Dudley & Shanley Inc. now owns 1,111,355 shares of the company’s stock valued at $28,417,000 after purchasing an additional 12,400 shares in the last quarter. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH purchased a new position in shares of Avantor during the first quarter valued at about $93,000. 95.08% of the stock is owned by institutional investors.
Avantor Stock Performance
Shares of AVTR opened at $24.10 on Friday. The stock has a 50-day moving average of $24.93 and a 200-day moving average of $22.46. The company has a market cap of $16.35 billion, a PE ratio of 50.21, a P/E/G ratio of 1.53 and a beta of 1.37. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.61 and a quick ratio of 1.05. Avantor has a one year low of $16.63 and a one year high of $26.16.
Avantor (NYSE:AVTR – Get Free Report) last posted its earnings results on Wednesday, February 14th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.03. Avantor had a return on equity of 14.11% and a net margin of 4.61%. The company had revenue of $1.72 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter last year, the company earned $0.32 earnings per share. The company’s revenue for the quarter was down 4.0% on a year-over-year basis. On average, equities research analysts predict that Avantor will post 1.01 EPS for the current fiscal year.
Avantor Company Profile
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
See Also
- Five stocks we like better than Avantor
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Comprehensive Analysis of PayPal Stock
- The 3 Best Retail Stocks to Shop for in August
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- Buy P&G Now, Before It Sets A New All-Time High
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.